Financing channel feed

Watch out, Pfiz­er: Affini­vax lands $226M in fund­ing to ad­vance Pre­vnar 13 ri­val as well as the rest of its pipeline

5 years ago

Iso­Plex­is scores big backer for per­son­al­ized pro­tein 'bar­codes' as Per­cep­tive jumps on board new fund­ing round

5 years ago

Nas­daq rings in its first biotech IPOs of 2021: a CAR-T spe­cial­ist from Chi­na, a can­cer port­fo­lio play, and a SPAC

5 years ago
China
Cell/Gene Tx

DiCE gets its 'li­brary' card ready as it speeds de­vel­op­ment of DNA data­base-de­rived mol­e­cules with more in­vestor cash

5 years ago

Mana joins the hec­tic fight against sol­id tu­mors with an ‘off-the-shelf’ can­di­date an­gling for an IND this year

5 years ago
Cell/Gene Tx

2020 brought a huge boom in health­care in­vest­ment. How big? SVB an­a­lysts have the record-break­ing an­swer

5 years ago

Ki­ra and its com­ple­ment-tar­get in­hibitors plot run to the clin­ic with new in­vestor cash just months af­ter un­cloak­ing

5 years ago

Rick Klaus­ner fronts cash for his fun­gus out­fit LifeM­ine and brings on No­bel lau­re­ate to fur­ther push can­cer dis­cov­ery

5 years ago
Startups

Look­ing to solve the sol­id tu­mor puz­zle box, Caris­ma aims to take 'CAR-M' ground­break­er in­to ear­ly-stage tri­al

5 years ago

With decades in gene ther­a­py un­der his belt, Ronald Crys­tal launch­es new ven­ture with up to 18 can­di­dates in the pipe

5 years ago
Startups

Gary Glick, Kei­th Fla­her­ty now have $270M to re­al­ize their vi­sion for Pre­ci­sion On­col­o­gy 2.0 — we'll just have to wait for the de­tails

5 years ago
Startups

Were­wolf pre­pares to bare its teeth in 1st tri­al for tar­get­ed cy­tokine tu­mor fight­ers with new round of in­vestor cash

5 years ago

Tim Lu’s quest to break new cell ther­a­py ground with gene cir­cuits gets Bay­er’s back­ing in a big new fi­nanc­ing round

5 years ago

With lessons learned from Vor, Sid­dhartha Mukher­jee takes a dif­fer­ent route to tar­get sol­id tu­mors with start­up Myeloid

5 years ago
Startups

Can a new pro­tein bring RNA drugs where they can't reach? J&J vet Sue Dil­lon's Io­n­is-part­nered biotech gets $88M to prove yes

5 years ago

Eli Lil­ly's transpa­cif­ic bo­som bud­dy Terns bags late-round fund­ing to dri­ve NASH hope­fuls through the clin­ic

5 years ago

A vet­er­an on­col­o­gy start­up crew is mak­ing a very se­ri­ous bet that they’ve found the key to un­lock­ing the promise of on­colyt­ic virus­es

5 years ago
Startups

It was the best of all pos­si­ble worlds in the worst of all times for biotech in 2020. What comes now?

5 years ago

More than 20 years in­to pro­teomics quest, So­ma­Log­ic keeps adding in­vestors as it nears a po­ten­tial pub­lic of­fer­ing

5 years ago

Dana-Far­ber backed Neo­morph hunts 'un­drug­gable' pro­teins with new round of in­vestor cash for hires, de­vel­op­ment

5 years ago

Pe­ter Thiel joins fund­ing round for pep­tide drug play­er in lat­est swing at emerg­ing biotech mar­ket

5 years ago
People

Months af­ter strik­ing SHP2 deal with Ab­b­Vie, Ja­co­bio pulls in $174M+ from Hong Kong IPO

5 years ago
China

Glax­o­SmithK­line makes big down pay­ment on biotech tar­get­ing 'syn­thet­ic vi­a­bil­i­ty' with start­up fund­ing, pipeline deals

5 years ago
Discovery

Google sis­ter Ver­i­ly sports an­oth­er im­pres­sive raise, haul­ing in $700M to sup­port its two big plat­forms

5 years ago
First page Previous page 84858687888990 Next page Last page
A service from the Financial Times